2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2815

A Comparison of Th17 Gene Expression in Psoriatic Arthritis Synovial Fluid and Peripheral Blood
Abstract Number: 275

A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis
Abstract Number: 396

A Comparison of the Illness Experience Reported Via the Patient Reported Outcomes Measurement Information System Between Patients with Childhood-Onset Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, and Widespread Chronic Musculoskeletal Pain
Abstract Number: 3242

A Comprehensive Method for Using Sensewear MiniTM Monitors to Explore Differences in Ambulatory Activities in People Living with and without Early Rheumatoid Arthritis: Moving Beyond Measuring Total Steps
Abstract Number: 849

A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Abstract Number: 294

A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease
Abstract Number: 1481

A Description of the Transition Aged Population in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 314

A Double-Blind, Randomized, Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular (IA) Injections of Fasitibant in Patients with Symptomatic OA of the Knee
Abstract Number: 1782

a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Abstract Number: 1411

A Double-Blind, Randomized, Placebo-Controlled Trial of Mesenchymal Stem Cells for the Treatment of Patients with Full-Thickness Rotator Cuff Tears
Abstract Number: 2505

A Fellow Led Quality Improvement Project for Improving Contraceptive Compliance in Women Receiving Teratogenic Medications
Abstract Number: 1810

A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort
Abstract Number: 104

A Genome-Wide Association Study Identifies SLC8A3 As a Susceptibility Locus for ACPA-Positive Rheumatoid Arthritis
Abstract Number: 2997

A Genome-Wide Association Study of a Hispanic Systemic Sclerosis Cohort
Abstract Number: 220

A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].